Letter to the Editor: Response In their letter, Thompson and Dahlqvist suggest that the findings of our paper describing the comparative adherence to anticholinergic drugs could be improved by the addition of details regarding the formulations used by patients in our cohort. They note that incidence of dry mouth-a commonly cited reason for drug discontinuation-is most often observed with immediate-release formulations. In Ontario, only immediate-release (IR) formulations of oxybutynin are funded through the public drug plan; consequently, 99.6% of patients initiating oxybutynin in our study were treated with an IR tablet formulation. However, both IR and extended-release (ER) formulations of tolterodine are publically funded in Ontario, and therefore only 58.9% of patients newly treated with tolterodine commenced treatment with an IR formulation. In response to Thompson's and Dahlqvist's comments, we replicated our previous analysis, comparing persistence among 31,990 patients initiating IR oxybutynin with that of 14,637 patients initiating IR tolterodine derived from our original cohort. Similar to our earlier study, we found a significant difference in persistence rates between people treated with IR oxybutynin and IR tolterodine (p<0.0001; Fig. 1 ). After 6 months of followup, only 30.6% of new IR oxybutynin users persisted with therapy compared to 45.9% of new IR tolterodine users.
These updated findings suggest that differences in adherence to oxybutynin and tolterodine persist among a subgroup of patients initiated on IR formulations. 
